Zydus Group Reports Real-World Study Results of Exemptia (biosimilar, adalimumab) for Ankylosing Spondylitis
- The company highlighted the real-world study in India evaluating adalimumab biosimilar Exemptia for 10wks., showed improvements in disease activity through 48wks., significant improvements at 4wk. were seen in pain VAS, patient global assessment, Health Assessment Questionnaire, ESR & CRP
- 82% achieved ASAS 20 at 12wks. and ASAS 40 (70%), 50% achieved an ASAS 20 response at each time point (4, 8, 12, 24, 36, and 48wks., and 42% demonstrated continued improvement in ASAS 20 index from 12-36wks., improvements in efficacy EPs at 12wk.
- None of the patients reported serious AEs, and no patients developed symptoms of TB, 10 with mild AEs, 11 withdrew from the study due to a poor therapeutic response while no patients withdrew due to AEs
Ref: Center For Biosimilar | Image: Zydus
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.